Clinical trial
A Continuation Study to Assess the Effect of CellCept in Patients With…
NCT00408213 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00408213 |
|---|---|
| Title | A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis. |
| Official title | A Randomized, Double-Blind Study to Evaluate the Safety of Continued Treatment With CellCept in Patients With Well-Controlled Myasthenia Gravis Receiving a Stable Dose of Prednisone |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Aspreva Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myasthenia Gravis Generalised |
| Intervention type | Drug |
| Interventions | mycophenolate mofetil [CellCept], Placebo |
| Enrollment | 136 |
| Start date | Jun 1, 2004 |
| Completion | Sep 1, 2007 |
| First posted | Dec 6, 2006 |
| Last update posted | May 23, 2008 |
| Countries | France, Germany, Italy, Serbia and Montenegro, Ukraine, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: